A rapidly increasing demand for genetic counseling resulting from the recent expansion of indications of PARPi among patients with ABC, as well as patients with ovarian and prostate cancer, with a deleterious BRCA1/2mut may be contributing to the relatively low rate of patients receiving genetic counseling observed in this study. The gene discussed is BRCA1; the disease is aneurysmal bone cyst.